Dr. René Levy, professor of pharmaceutics and former chair of the pharmaceutics department, is one of five UW faculty members to be named as a fellow of the American Association for the Advancement of Science (AAAS) Council.

   Election as a Fellow of AAAS is an honor bestowed upon members by their peers. “I am grateful for this reconnection,” says Levy. “To be chosen as a Fellow by a group of my peers it a fulfilling honor indeed.”

   Dr. Levy is noted for his contributions in the section of pharmaceutical science, where he is specifically recognized for his distinguished contributions to the treatment of epilepsy, and for fostering the development and rational use of new drugs and therapeutic modalities.

   Levy joined the UW faculty in 1970, after earning his doctorate in pharmaceutical chemistry from the University of California, San Francisco. He is the founder of the Metabolism and Transport Drug Interaction Database (MTDID) presently licensed by UWTechTransfer to pharmaceutical scientists throughout the world. For the past 5 years, the MTDID has been recognized as one of the top ten royalty income generators for the University of Washington. Levy and his colleagues will be recognized at the 2008 AAAS Annual Meeting to be held this coming February in Boston.

   Levy and UW colleagues, Aimee H. Bakken, Toby Bradshaw Jr., Conway B. Leovy and Dennis P. Lettenmaier, are among 471 association members to be recognized for their scientifically or socially distinguished efforts to advance science and/or its technological applications.

   AAAS is the world's largest general scientific society and publisher of the journal, Science. AAAS was founded in 1848 and boasts 262 affiliated societies and academies of science. According to material from AAAS, Science has the largest paid circulation of any peer-reviewed general science journal, with an estimated readership of 1 million.